The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This analysis takes a first look at how hospitals are reporting prices under updated federal hospital price transparency requirements that took effect in January 2026.
With the 2026 midterms about a month away, health care costs remain tied with gas as voters’ top midterm concerns and the Democrats hold a clear edge over the Republicans Party on who voters trust to handle many top electoral issues, including the cost of health care and the cost of living. Two-thirds of U.S. adults now favor Medicare-for-all, a new high in KFF Polling, but support shifts when competing claims from critics and proponents…
TrumpRx prices for brand-name drugs are about as likely to be higher as lower compared to average prices in other wealthy countries, according to an analysis that compares 32 brand-name drugs (without generics or biosimilars) on the TrumpRx website with publicly available prices in one or more of 11 OECD member countries.
Consumers who buy brand-name prescription drugs without an available generic or biosimilar at the prices available through the new TrumpRx website are about as likely to pay more as pay less for those drugs relative to the publicly listed prices available in other comparatively wealthy countries, a new KFF analysis finds. The Trump administration has promoted the TrumpRx website as a way for consumers to get the lowest prices for prescription medications in the world, drawing on…
This report examines how LGBTQ+ adults' experiences with health care costs and access compare to those of non-LGBTQ+ adults, finding that LGBTQ+ adults face significantly greater challenges affording and accessing care.
This analysis finds that CMS’s proposed cut to Medicare reimbursement for 340B drugs, and accompanying increase for other outpatient services, would reduce revenues among safety-net hospitals while increasing revenues among for-profit hospitals.
In this JAMA Health Forum post, KFF's Larry Levitt outlines four reasons why high drug prices are in the spotlight more than hospital prices, even though hospitals accounted for 40% of the growth in national health spending from 2022 to 2024, and explores the potential for policy action to restrain them.
This brief compares the prices paid by private insurers for hospital care to increases in Medicare payment using data from the Bureau of Labor Statistics (BLS) Producer Price Index (PPI), finding that hospital prices have risen much faster for private insurance than Medicare since 2019.
Extending the short-term GLP-1 Bridge program is good news for eligible Medicare beneficiaries because it provides the certainty of obesity drug coverage at a $50 copay for a longer duration, but federal spending will also rise by some unknown amount since CMS hasn’t disclosed the projected cost.
In this JAMA Health Forum column, KFF's Larry Levitt examines the criticism that health insurance companies are facing from political leaders, and explores the industry's role in both causing and addressing some of the health systems' biggest problems, including rising costs and prior authorization review.
© 2026 KFF
